Journal of Jilin University(Medicine Edition) ›› 2024, Vol. 50 ›› Issue (3): 638-646.doi: 10.13481/j.1671-587X.20240307
• Research in basic medicine • Previous Articles Next Articles
Jiacai FU1,2,Lingsha QING2,Lu YANG2,Meihui SONG2,Xianying ZHANG2,Xiaocui LIU2,Fengjin LI2(
),Ling QI2(
)
Received:2023-06-13
Online:2024-05-28
Published:2024-07-01
Contact:
Fengjin LI,Ling QI
E-mail:wklifengjin@163.com;qiling1718@gzhmu.edu.cn
CLC Number:
Jiacai FU,Lingsha QING,Lu YANG,Meihui SONG,Xianying ZHANG,Xiaocui LIU,Fengjin LI,Ling QI. Inhibitory effect of Schisandrin B on proliferation of pancreatic cancer Pan02 cells and its mechanism[J].Journal of Jilin University(Medicine Edition), 2024, 50(3): 638-646.
Tab. 1
Proliferation rates of Pan02 cells after treated with different concentrations of Schisandrin B detected by CCK-8 method"
| Group | |||
|---|---|---|---|
| 48 | 72 | ||
| 0 | 52.0 | 77.8 | 75.8 |
| 0.78 | 52.0 | 77.6 | 67.2 |
| 1.56 | 50.9 | 76.6 | 58.3 |
| 3.12 | 51.1 | 72.2 | 47.3 |
| 6.25 | 51.8 | 70.4 | 44.8 |
| 12.50 | 52.1 | 66.9 | 38.7 |
| 25.00 | 52.0 | 66.7 | 37.3 |
| 1 | KLEIN A P. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(7): 493-502. |
| 2 | TORPHY R J, FUJIWARA Y, SCHULICK R D. Pancreatic cancer treatment: better, but a long way to go[J]. Surg Today, 2020, 50(10): 1117-1125. |
| 3 | MCGUIGAN A, KELLY P, TURKINGTON R C, et al. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes[J]. World J Gastroenterol, 2018, 24(43): 4846-4861. |
| 4 | JAAKS P, COKER E A, VIS D J, et al. Effective drug combinations in breast, colon and pancreatic cancer cells[J]. Nature, 2022, 603(7899): 166-173. |
| 5 | HO W J, JAFFEE E M, ZHENG L. The tumour microenvironment in pancreatic cancer—clinical challenges and opportunities[J]. Nat Rev Clin Oncol, 2020, 17: 527-540. |
| 6 | HU Y W, LI H T, LI R L, et al. Protective effects of Schisandrin B against D-GalN-induced cell apoptosis in human hepatocyte (L02) cells via modulating Bcl-2 and Bax[J]. Bioengineered, 2021, 12(1): 7205-7214. |
| 7 | LUO W, LIN K, HUA J Y, et al. Schisandrin B attenuates diabetic cardiomyopathy by targeting MyD88 and inhibiting MyD88-dependent inflammation[J]. Adv Sci, 2022, 9(31): e2202590. |
| 8 | YAN L S, ZHANG S F, LUO G, et al. Schisandrin B mitigates hepatic steatosis and promotes fatty acid oxidation by inducing autophagy through AMPK/mTOR signaling pathway[J]. Metabolism, 2022, 131: 155200. |
| 9 | LI Z M, ZHAO L J, XIA Y S, et al. Schisandrin B attenuates hepatic stellate cell activation and promotes apoptosis to protect against liver fibrosis[J]. Molecules, 2021, 26(22): 6882. |
| 10 | TAN S R, ZHENG Z, LIU T Q, et al. Schisandrin B induced ROS-mediated autophagy and Th1/Th2 imbalance via selenoproteins in Hepa1-6 cells[J]. Front Immunol, 2022, 13: 857069. |
| 11 | LI S P, WANG H, MA R D, et al. Schisandrin B inhibits epithelial-mesenchymal transition and stemness of large-cell lung cancer cells and tumorigenesis in xenografts via inhibiting the NF-κB and p38 MAPK signaling pathways[J]. Oncol Rep, 2021, 45(6): 115. |
| 12 | JIANG Y, ZHANG Q L, BAO J S, et al. Schisandrin B inhibits the proliferation and invasion of glioma cells by regulating the HOTAIR-micoRNA-125a-mTOR pathway[J]. Neuroreport, 2017, 28(2): 93-100. |
| 13 | NASSER M I, HAN T Y, ADLAT S, et al. Inhibitory effects of Schisandrin B on human prostate cancer cells[J]. Oncol Rep, 2019, 41(1): 677-685. |
| 14 | PFAB C, ABGARYAN A, DANZER B, et al. Ceftazidime and cefepime antagonize 5-fluorouracil’s effect in colon cancer cells[J]. BMC Cancer, 2022, 22(1): 125. |
| 15 | ICARD P, FOURNEL L, WU Z R, et al. Interconnection between metabolism and cell cycle in cancer[J]. Trends Biochem Sci, 2019, 44(6): 490-501. |
| 16 | JR R R. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs[J]. Pharmacol Res, 2019, 139: 471-488. |
| 17 | LIU Y X, DONG Y Y, ZHAO L P, et al. TRIM59 overexpression correlates with poor prognosis and contributes to breast cancer progression through AKT signaling pathway[J]. Mol Carcinog, 2018, 57(12): 1792-1802. |
| 18 | KUMARI S, KUMAR P, KUMAR M, et al. Expression of p27 and p16 and their clinical significance in gastric cancer[J]. Clin Transl Oncol, 2021, 23(4): 856-865. |
| 19 | SINGH R, LETAI A, SAROSIEK K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins[J]. Nat Rev Mol Cell Biol, 2019, 20(3): 175-193. |
| 20 | WARREN C F A, WONG-BROWN M W, BOWDEN N A. BCL-2 family isoforms in apoptosis and cancer[J]. Cell Death Dis, 2019, 10(3): 177. |
| 21 | SONG L J, CHEN X, MI L, et al. Icariin-induced inhibition of SIRT6/NF-κB triggers redox mediated apoptosis and enhances anti-tumor immunity in triple-negative breast cancer[J]. Cancer Sci, 2020, 111(11): 4242-4256. |
| 22 | ABARIKWU S O, FAROMBI E O. Atrazine induces apoptosis of SH-SY5Y human neuroblastoma cells via the regulation of Bax/Bcl-2 ratio and caspase-3-dependent pathway[J]. Pestic Biochem Physiol, 2015, 118: 90-98. |
| 23 | WAGNER A K, AMIN K B, NIYONKURU C, et al. CSF Bcl-2 and cytochrome C temporal profiles in outcome prediction for adults with severe TBI[J]. J Cereb Blood Flow Metab, 2011, 31(9): 1886-1896. |
| 24 | PEÑA-BLANCO A, GARCÍA-SÁEZ A J. Bax, Bak and beyond - mitochondrial performance in apoptosis[J]. FEBS J, 2018, 285(3): 416-431. |
| 25 | SIDDIQUI W A, AHAD A, AHSAN H. The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update[J]. Arch Toxicol, 2015, 89(3): 289-317. |
| [1] | Yang LI,Shiyang LI,Hongmei ZHANG,Qianqian LIU,Yubing CHEN. Effect of NGFR gene expression differences on promotion of apoptosis of squamous cell carcinoma and adenocarcinoma cells by PD-1 inhibitor-activated T lymphocytes [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 680-693. |
| [2] | Qiaotong REN,Weihua WU,Xingxiang WANG,Shichao WANG,Yipeng CHENG,Chun LI. Effect of interleukin-17 recepter B gene silencing on proliferation, invasion and apoptosis of lung adenocarcinoma A549 cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 738-745. |
| [3] | Qiuping SU,Lei XING,Wei ZHANG,Shan JIANG,Yangyang ZHAO,Fangfang CHEN. Research progress in anti-tumor mechanism of berberine and application of its novel nano-delivery system in tumor therapy [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 863-871. |
| [4] | Jie YU,Zongkang WANG,Xun LIU,Yanan YANG,Jin TAN. Effect of miR-153-3p/PGC-1α axis on apoptosis of oral squamous cell carcinoma cells by modulation of mitochondrial apoptosis pathway [J]. Journal of Jilin University(Medicine Edition), 2026, 52(2): 348-358. |
| [5] | Yaping LI,Chunyan TAN,Lujie ZHAO,Jiayi ZHAO,Ting LI,Xiao YANG,Xiaoyun YANG. Inductive effect of lysophosphatidic acid combined with 6-hydroxydopamine on apoptosis of SH-SY5Y cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 152-161. |
| [6] | Jiaxin WANG,Junwen MAO,Xuan ZHANG. Expression of natural autoantibodies against apoptosis inhibitory genes in plasma of patients with hepatocellular carcinoma and its clinical significance [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 228-235. |
| [7] | Huaimin LIANG,Jiacheng JIN,Wenhua CHEN,Yuyao LI,Hangyu WANG,Ke ZHANG,Jinhui WANG. UPLC-Q-TOF/MS and network pharmacology analysis and experimental verification based on potential active ingredients and mechanisms of medicinal Mulberry Leaves in anti-acute kidney injury [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 56-69. |
| [8] | Shanshan SUN,Mei LU,Xinfu GAO,LYu Guangyao,Baolei Zhao,LYu Wenwen. Inhibitory effect of Bradykinin 1 receptor antagonist ELN441958 on proliferation of HepG2 cells by regulating Akt/FoxO3a signaling pathway [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 70-80. |
| [9] | Xiaohan YAO,Mingchen YAO,Zhiqing WANG,Heyang LI,Yan YAN,Ningjing LEI. Effect of silencing GPR139 gene on proliferation, apoptosis and autophagy of breast cancer cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 1-9. |
| [10] | Dayou DAI,Zhigang ZHANG,Hui LI. Effect of CHRNA5 in occurrence and development of pancreas cancer and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(6): 1518-1531. |
| [11] | Han XUE,Yuxin FAN,Ting ZHANG,Zhimin LI,Mingge HUO,Xingang GUAN. Preparation of nanodrug PTX2 NPs and its killing effect on human lung cancer A549 cells [J]. Journal of Jilin University(Medicine Edition), 2025, 51(5): 1260-1266. |
| [12] | Jiarui LI,Zhenlin YANG,Fan GAO,Jingjing GUO,Jinzi LI. Effect of miR-34a-5p on hippocampal neuron apoptosis in rats with temporal lobe epilepsy and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 939-947. |
| [13] | Panxi SUN,Xue QIN,Chongyang ZHANG,Jia LUO,Yong CHEN,Lili WEI. Protective effect of TUG-891 on ischemic stroke induced by ischemia and hypoxia and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 968-975. |
| [14] | Cheng CHEN,Jingyao LI,Wanxiang HU,Donghui LIU,Zhihong CHEN. Protective effect of sericin on streptozotocin-induced INS-1 cell damage by regulating PI3K/Akt/NF-κB signaling pathway through Akt1 and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 590-598. |
| [15] | Donghui LIU,Yunzhe CI,Chunyan WANG,Wenyi MA. Effect of miR-199a-5p on expression of Caveolin-1, cell migration and apoptosis in glioma U251 cells [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 663-671. |
|